secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001493152-26-013785
Event type: regulatory
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Telomir Pharmaceuticals submits IND to FDA for Telomir-1 in metastatic triple-negative breast cancer
--------------------------------------------------------------------------------

- IND submitted March 31, 2026 for oral Telomir-Zn (Telomir-1) in advanced/metastatic TNBC.
- Data from IND-enabling pharmacology, toxicology, and manufacturing studies included in submission.
- Planned Phase 1/2 trial: 3+3 dose-escalation, then Simon two-stage with ORR as primary endpoint.
- Preclinical GLP safety studies showed no treatment-related adverse or dose-limiting toxicities.
- Telomir-1 reduces redox-active iron and increases zinc, inhibiting iron-dependent histone demethylases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000149315226013785/0001493152-26-013785-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000149315226013785/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-013785

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer